Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer
- 15 March 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (6), 999-1006
- https://doi.org/10.1200/jco.2003.05.068
Abstract
Purpose: Bexarotene is a retinoid X receptor–selective retinoid that has preclinical antitumor activity in breast cancer. We evaluated the efficacy and safety of oral bexarotene in the treatment of patients with metastatic breast cancer. Patients and Methods: The following three groups of patients were treated: hormone-refractory, chemotherapy-refractory, and tamoxifen-resistant patients. Patients in the first two groups were treated with bexarotene alone, whereas the tamoxifen-resistant patients received both tamoxifen and bexarotene. Patients in all groups were randomly assigned to receive bexarotene at either 200 or 500 mg/m2/d. Results: One hundred forty-eight patients were randomized; 145 patients were treated. Of 48 hormone-refractory patients, there were two partial responses (6%) and 10 patients with stable disease lasting more than 6 months; of 47 chemotherapy-refractory patients, there were two partial responses (6%) and five patients with stable disease; and of 51 tamoxifen-resistant patients, there was one partial response (3%) and 11 patients with stable disease. All partial responses occurred at the 200-mg/m2/d dose. The projected median time to progression across all of the arms was 8 to 10 weeks. There were no drug-related deaths, and only two patients had drug-related serious adverse events. The most common drug-related adverse events were hypertriglyceridemia (84%), dry skin (34%), asthenia (30%), and headache (27%). There were no cases of pancreatitis. Conclusion: The efficacy of bexarotene in patients with refractory metastatic breast cancer is limited. However, it is an oral agent with minimal toxicity and a unique mechanism of action, which produced clinical benefit in approximately 20% of patients. Future efforts should define populations likely to benefit from this agent.Keywords
This publication has 21 references indexed in Scilit:
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and BeyondThe Oncologist, 2001
- Treatment of Breast CancerNew England Journal of Medicine, 1998
- Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.Journal of Clinical Oncology, 1996
- Retinoid ReceptorsPublished by Elsevier BV ,1993
- Multiplicity generates diversity in the retinoic acid signalling pathwaysTrends in Biochemical Sciences, 1992
- HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosisClinical and Experimental Immunology, 1990
- Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemiaBlood, 1988
- The Steroid and Thyroid Hormone Receptor SuperfamilyScience, 1988
- Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid.Proceedings of the National Academy of Sciences of the United States of America, 1980